BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

LifeScience Antibody Drug Conjugates

Mango Sciences Partners with ImmunoACT to Expand Access to NexCAR19 CAR-T Therapy in India

Mango Sciences, Inc., the Boston, US, and Bengaluru, IN-based data and AI company, announced a strategic partnership with ImmunoAdoptive Cell Therapy (Immu...

December 08, 2025 | News

Biocytogen Announces FDA IND Clearance for IDE034 Bispecific B7H3 PTK7 ADC Licensed to IDEAYA Biosciences

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), announced that its partner IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision o...

December 08, 2025 | News

Neurimmune And Alexion Expand Global Collaboration To Advance NI009 For Light Chain Amyloidosis

Neurimmune announced that it has expanded on its transthyretin amyloid cardiomyopathy (ATTR-CM) collaboration with Alexion, AstraZeneca Rare Disease ...

December 05, 2025 | News

Imugene and JW Therapeutics Launch First-in-Class “Mark and Kill” Solid Tumor Collaboration

Imugene and JW Therapeutics (Shanghai) Co., LTD have entered a strategic collaboration to evaluate a novel combination therapy using Imugene's onCARlytic...

December 01, 2025 | News

BioDlink Drives Global Biologics Innovation with World’s First Approved EGFR-Targeted ADC

Recognized as Biologics CDMO of the Year, BioDlink shares insights into the world's first approved EGFR-targeted ADC for recurrent/metastatic nasopharyng...

December 01, 2025 | News

Mabwell Doses First Patient in Phase One Two Study of Novel CDH17 Targeting ADC 7MW4911 for Advanced Solid Tumours

Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that the first patient has been dosed...

November 26, 2025 | News

Harbour BioMed Deepens Global Collaboration with AstraZeneca to Advance Next Generation Biotherapeutics

Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody ...

November 25, 2025 | News

China Marks a Landmark Moment as BioDlink and Lepu Biopharma Launch the World’s First EGFR Targeting ADC

Celebrating a Shared Milestone: BioDlink and Lepu Biopharma celebrated the launch of MEIYOUHENG®, the world's first EGFR-Targeting ADC, and their par...

November 24, 2025 | News

Vaxcellbio’s CSO Outlines How DDS Enabled Nanobodies Could Redefine Global Treatment Pathways

Vaxcellbio is betting on the combined power of nanobodies and advanced drug delivery science to push boundaries across ophthalmology and other chronic dise...

November 20, 2025 | Interaction

Akeso Initiates First-in-Human Trial of Personalised mRNA Vaccine AK154 for Pancreatic Cancer

Akeso, Inc. (HKEX: 9926. HK) is pleased to announce that the first patient has been dosed in a Phase I clinical trial evaluating the personalized mRNA vacc...

November 11, 2025 | News

BioDlink and Lepu Biopharma Achieve China Approval for First-in-Class EGFR-Targeted ADC in Nasopharyngeal Carcinoma

BioDlink helps Lepu Biopharma win China's marketing approval for EGFR-targeted ADC treating recurrent or metastatic nasopharyngeal carcinoma T...

November 06, 2025 | News

Akeso Secures Fourth Breakthrough Therapy Designation for Ivonescimab in Combination Therapy for Triple-Negative Breast Cancer

Akeso (9926.HK) announced that its first-in-class bispecific antibody, ivonescimab (PD-1/VEGF bispecific antibody), in combination with chemotherapy for fi...

November 04, 2025 | News

SK pharmteco and LOTTE BIOLOGICS Join Forces to Build Fully Integrated Global ADC CDMO Platform

Two global CDMO leaders have joined forces to strengthen their presence in the rapidly growing antibody-drug conjugate (ADC) market. The collaboration w...

October 30, 2025 | News

Harbour BioMed Unveils Generative AI HCAb Model to Redefine Antibody Discovery and Development

Harbour BioMed (HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immu...

October 29, 2025 | News

Stay Connected